Source: Business Standard

Cipla: Cipla share price jumps 5% as USFDA okays cancer drug Paclitaxel

Cipla said USFDA has approved the ANDA submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial ('Protein-bound Paclitaxel') on Apr 10

Read full article »
Annual Revenue
$1.0-5.0B
Employees
10-50K
Umang Vohra's photo - Managing Director & CEO of Cipla

Managing Director & CEO

Umang Vohra

CEO Approval Rating

57/100

Read more